Roscovitine and purvalanol A effectively reverse anthracycline resistance mediated by the activity of aldo-keto reductase 1C3 (AKR1C3): A promising therapeutic target for cancer treatment
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
30077642
DOI
10.1016/j.bcp.2018.08.001
PII: S0006-2952(18)30320-4
Knihovny.cz E-zdroje
- Klíčová slova
- AKR1C3, Anthracyclines, Cyclin-dependent kinase, Drug resistance, Inhibition,
- MeSH
- antracykliny farmakologie MeSH
- buňky Hep G2 MeSH
- chemorezistence účinky léků MeSH
- HCT116 buňky MeSH
- klonování DNA MeSH
- lidé MeSH
- nádory farmakoterapie MeSH
- protein AKR1C3 genetika metabolismus MeSH
- protinádorové látky aplikace a dávkování farmakologie MeSH
- puriny aplikace a dávkování chemie farmakologie MeSH
- regulace genové exprese u nádorů účinky léků MeSH
- roskovitin aplikace a dávkování chemie farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Názvy látek
- 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine MeSH Prohlížeč
- AKR1C3 protein, human MeSH Prohlížeč
- antracykliny MeSH
- protein AKR1C3 MeSH
- protinádorové látky MeSH
- puriny MeSH
- roskovitin MeSH
Members of the short-chain dehydrogenase/reductase (SDR) and aldo-keto reductase (AKR) superfamilies mediate the reduction of anthracyclines to their less potent C-13 alcohol metabolites. This reductive metabolism has been recognized as one of the most important factors that trigger anthracycline resistance in cancer cells. In our study, two purine analogues, purvalanol A and roscovitine, were identified as effective inhibitors of aldo-keto reductase 1C3 (AKR1C3), an enzyme that is overexpressed in many cancer types and is also a key player in tumour cell resistance to anthracyclines. Purvalanol A and roscovitine potently inhibited human recombinant AKR1C3 (Ki = 5.5 μM and 1.4 μM, respectively) and displayed similar activity in experiments with intact cells. Ligand-protein docking calculations suggested that both inhibitors occupied a part of the cofactor-binding site. Furthermore, we demonstrated that the combination of daunorubicin with purvalanol A or roscovitine exhibited a synergistic effect in AKR1C3 overexpressing cells. Based on these findings, it is possible to presume that purvalanol A and roscovitine may have the potential to enhance the therapeutic effectiveness and safety of anthracyclines via inhibition of AKR1C3.
Citace poskytuje Crossref.org
Targeting Pharmacokinetic Drug Resistance in Acute Myeloid Leukemia Cells with CDK4/6 Inhibitors
